Stay updated with breaking news from Term Infants. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs...
New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - read this article along with other careers information, tips and advice on BioSpace
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.